Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class

It's been a long road for RNA interference (RNAi): From a Nobel prize and overpriced deals more than a decade ago, to the Food and Drug Administration approval of the second RNAi drug this week.